Nateglinide restores early-phase insulin secretion to feeding and reduces postprandial hyperglycaemia in type 2 diabetes. This study evaluated the effects of nateglinide on dipeptidyl peptidase-IV (DPP-IV) activity and glucose-dependent insulinotropic polypeptide (GIP) degradation. Research design and methods Blood samples were collected from type 2 diabetic subjects (n=10, fasting glucose 9.36+/-1.2 mmol/l) following administration of oral nateglinide (120 mg) 10 min prior to a 75 g oral glucose load in a randomised crossover design.
- insulin secretion
- postprandial hyperglycaemia
McKillop, A., Duffy, N., Lindsay, J., Green, B., Patterson, S., O'Harte, F., Bell, P., & Flatt, P. (2009). Insulinotropic actions of nateglinide in type 2 diabetic patients and effects on dipeptidyl peptidase-IV activity and glucose-dependent insulinotropic polypeptide degradation. European Journal of Endocrinology, 161(6), 877-885. https://doi.org/10.1530/EJE-09-0547